Thermo Fisher Scientific Inc., Illumina, Inc., and Bio rad laboratories Inc., are Dominating the Global Human Leukocyte Antigen (HLA) typing for Transplant Market in 2021

Global Human Leukocyte Antigen (HLA) Typing for Transplant Market is expected to grow with the CAGR of 7.9% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-hla-typing-transplant-market

Global human leukocyte antigen (HLA) typing for transplant market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in global human leukocyte antigen (HLA) typing for transplant market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In December 2020, a strategic acquisition was done between BD.  and C. R. Bard, Inc. to improve both company’s treatment process for diseases to get better patient outcomes, thereby anticipated in improving company’s overall presence and income.

Thermo Fisher Scientific Inc. is the dominating player in global human leukocyte antigen (HLA) typing for transplant market. The other key players existing in the market includes are Illumina, Bio Rad Labaratories, Inc , Qiagen. , Roche Sequencing ( a subsidiary of F. HOFFMAN-LA ROCHE LTD.) , CareDX, Inc , Immucor Inc , Creative Biolabs , Luminex Corporation , acquired by DiaSorin in 2021 , Biofortuna Limited , Takara Bio Inc. , Omixon Inc. , FUJIREBIO , BD, TBG Diagnostics Limited. and GenDx among others.

Human Leukocyte Antigen (HLA) Typing for Transplant MarketThermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. was founded in 1956, and is headquartered in Massachusetts, U.S. The company mainly focuses on making the world healthier, cleaner and safer by enabling their customers and support them in improving patient’s therapies and diagnostics. It has following business segments life sciences solutions, analytical instruments, specialty diagnostics and laboratory products and services in which specialty diagnostics is the market focused segment. The company also provides various product launches including application & techniques in which the market focus products lie under techniques.

For instance,

  • In March 2021, Thermo Fisher Scientific Inc. announced that they have completed the FDA listing of their product and will be launching their Biosystems QuantStudio 5 Dx Real-Time PCR System. This product launch is expected to increase revenue generation of the company

The company has wide presence Asia-Pacific, Europe, Middle East and Africa, South America, and North America. The company also has subsidiaries companies such as Thermo Informatics Asia Pacific Pty Ltd. (South Australia), Thermo Gamma-Metrics Holdings Pty Ltd.( Australia), Thermo Electron LED S.A.S. (Germany), Thermo Trace Ltd.(Australia)  Thermo Finnigan Australia Pty. Ltd. (Australia) among others.

Illumina, Inc.

Illumina, Inc. was founded in 1998 and is headquartered in California, United States. The company is focused on applying innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. The company provides various product categories including instruments, kits and reagents, selection tools, software & analysis, services, popular products in which the market focus products lie under kits and reagents. The company has initiated many strategic initiatives to expand its market.

For instance,

  • In September 2019, Illumina, Inc. went under collaboration with the Broad Institute of MIT and Harvard for the development of secondary genomic software and algorithms. The company is investing for such innovation in order to deliver best- in –class open source software for common genomic testing methods. This initiative boosted the clinical adoption of sequencing methods by decreasing the overall cost and time of genome analysis.

The company has wide presence across Americas, Europe, Asia, and Middle East and Africa. The company also has various subsidiary companies such as Illumina K.K. (Japan), Illumina Singapore Pte. Ltd (Singapore), Illumina Australia Pty. Ltd (Australia), Illumina UK, Ltd (UK), Illumina Netherlands B.V. (Netherlands) among others.

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. was founded in 1952, and is headquartered in California, U.S. The company focuses on distributing and manufacturing life science products, analytical instrumentation & clinical diagnostics. The company offers analyzers, and clinical materials among others. It has following business segments life sciences and clinical diagnostics in which clinical diagnostics is the market focused segment. The company also provides various product categories including life science research, clinical diagnostics, process separations, food science and life science education in which the market focus products clinical diagnostics.

For instance,

  • In August 2021, Bio-Rad Laboratories, Inc. announced that management will participate in a Fireside Chat at the 2021 Virtual Wells Fargo Healthcare Conference. It helped the company to inform about improved healthcare and their products and services in the conference.

The company has presence worldwide in Europe, Asia, North America, and Latin America.  The company has various subsidiary companies such as Bio-Rad Korea (Korea), Bio-Rad Laboratories S.r.l. (Italy), Bio Rad SA (Canada), Bio-Rad Laboratories G.m.b.H. (Germany), Bio Rad Laboratories (India) Private ltd (India) among others. The company has initiated many strategic initiatives to expand its market.